ULTOMIRIS DSHP

ULTOMIRIS DSHP

ULTOMIRIS DSHP (Ravulizumab-cwvz) is an FDA-approved monoclonal antibody infusion therapy indicated for the treatment of paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS) in adult patients. Each single-dose, preservative-free 1×3 mL vial contains 300 mg of Ravulizumab-cwvz at 100 mg/mL, formulated for intravenous administration under professional supervision.

Ravulizumab works by inhibiting complement protein C5, preventing the formation of the membrane attack complex and reducing hemolysis and organ damage associated with complement-mediated disorders. This targeted therapy provides long-acting complement inhibition, improving patient outcomes and quality of life.

InfusionMed USA, headquartered in Carrollton, Texas, supplies ULTOMIRIS DSHP and other specialty hematology infusion therapies to hospitals, clinics, and infusion centers across Dallas, McKinney, Frisco, Plano, Lewisville, The Colony, and surrounding North Texas areas. We ensure cold-chain integrity, proper handling, and timely delivery for licensed healthcare providers.

For professional use only.

Download Form